The Integration of DFMO and ALK Inhibitors
By 2026, the introduction of Eflornithine (DFMO) has marked a significant milestone as the first FDA-approved maintenance therapy specifically aimed at preventing neuroblastoma relapse.
Given as an oral medication for two years following immunotherapy, DFMO targets the polyamine pathway that neuroblastoma cells depend on for growth. Simultaneously, for the 10-15% of patients whose tumors harbor ALK gene mutations, the use of targeted ALK inhibitors like Lorlatinib or Crizotinib has become a standard addition to frontline therapy. These precision drugs allow clinicians to attack the specific genetic drivers of a child's unique tumor, significantly improving the prognosis for what was previously an "ultra-high-risk" subset of patients.
2 Views